49 reports

WE HAVE A DRUG CALLED MEDACULINE, WHICH WAS FOR TUBERCULOSIS.

  • Biosimilar
  • World
  • Market Size
  • AbbVie Inc.
  • Sanofi S.A.

WE HAVE A DRUG CALLED MEDACULINE, WHICH WAS FOR TUBERCULOSIS.

  • Biosimilar
  • World
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • 7.1 BY PRODUCT CLASS
  • 7.1 BY PRODUCT CLASS

Report Global Biosimilars Market (2018 - 2023) Mordor Intelligence +## ##-##-## | No. ## Padma Nilaya, RT Nagar, Bengaluru, India ## ## | info@mordorintelligence. com ##.

  • Biosimilar
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • PERCENTAGE OF PATIENTS EXPERIENCING ADVERSE EVENTS WITH INFLIXIMAB BIOSIMILARS

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of the colon and rectum. As a result, the colon’s ability to absorb water is decreased, which leads to progressive loosening...

  • Biosimilar
  • Market Size
  • EA Pharma Co., Ltd.
  • Pfizer Inc.
  • Remicade group

Global Biosimilar Market: Size, Trends & Forecasts (2016-2020) November 2016 ##.

  • Biosimilar
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Enbrel has a boxed warning in its package insert noting an increased risk of cancer malignancies, tuberculosis, reactivation of tuberculosis, and other opportunistic infections associated with its use.

  • Biosimilar
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novartis AG

" Cost to patients is the number one issue [unmet need], number one. "

  • Biosimilar
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Remicade group

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

THE BOXED WARNING IN THE HUMIRA PACKAGE INSERT NOTES AN INCREASED RISK OF CANCER, TUBERCULOSIS (TB), AND OTHER OPPORTUNISTIC INFECTIONS ASSOCIATED WITH ITS USE.

  • Biosimilar
  • AbbVie Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Remicade group

REMICADE HAS A BOXED WARNING NOTING AN INCREASED RISK OF CANCER, TUBERCULOSIS (TB), AND OTHER OPPORTUNISTIC INFECTIONS.

  • Biosimilar
  • United States
  • AbbVie Inc.
  • Celgene Corporation
  • Remicade group

THE MIX CAN BE MADE AVAILABLE IN A VARIED RATIO (##:## OR ##:##).

  • Biosimilar
  • North America
  • United States
  • World
  • Market Size

E N B R E L ( E T A N E R C E P T; AMGEN/ PFIZER/ TAKEDA/ GLAXOSMITHKLINE) IS PREFERRED FOR PATIENTS AT HIGH RISK OF RE-ACTIVATION OF TUBERCULOSIS.

  • Autoimmune Disease
  • Biosimilar
  • Therapy
  • United States
  • ESI Group

INLEUSIN IS USED IN THE TREATMENT OF RENAL CELL CARCINOMA (KIDNEY CANCER), METASTATIC MELANOMA (SKIN CANCER), AND THORATIC FLUID BUILD-UP CAUSED BY CANCER AND TUBERCULOSIS.

  • Biosimilar
  • United States
  • Hospira, Inc.
  • Roche Group
  • Sandoz Inc.

A quorum shall exist if a majority of the total number of Directors is present, which majority must include at least one (##) Director designated by Agila and one (##) Director designated by Pfenex.

  • Biosimilar
  • Biotech
  • Pharmaceutical
  • Deals & Alliance
  • Wildwood Ventures Limited
  • BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2023 (USD MILLION)

Infectious diseases include cholera, hepatitis, tuberculosis, and influenza, among other diseases.

  • Biosimilar
  • Monoclonal Antibody
  • North America
  • United States
  • Market Size
  • MACULAR EDEMA - PIPELINE BY LUPIN LTD, H2 2017

THE INVENTION RELATES TO A PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE LIPOSOME, AT LEAST ONE POLYVALENT COUNTER ION DONOR OR A PHARMACEUTICALLY ACCEPTABLE SALT, AT LEAST ONE MONOVALENT COUNTER ION DONOR OR A PHARMACEUTICALLY ACCEPTABLE SALT, AND AN AMPHIPATHIC THER

  • Biosimilar
  • Therapy
  • Taiwan
  • World
  • Promedior, Inc.

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Biosimilar
  • Pharmaceutical
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.

For serious AEs the ER/ ##PY was ##. ##, and for serious infections it was ##. ##, with ## confirmed case of active tuberculosis.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • Therapy
  • United States

GlobalData Celltrion Inc reported one pharmaceuticals & healthcare deal in YTD 2018.

  • Biosimilar
  • Monoclonal Antibody
  • South Korea
  • Corporate Finance
  • Celltrion, Inc.
  • JUN 27, 2017: SANDOZ RECEIVES APPROVAL IN EUROPE FOR ERELZI (BIOSIMILAR ETANERCEPT) TO TREAT MULTIPLE INFLAMMATORY DISEASES

For serious AEs the ER/ ##PY was ##. ##, and for serious infections it was ##. ##, with ## confirmed case of active tuberculosis.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • EQUITY OFFERING

Strides Shasun' s products find applications in the treatment of diseases such as AIDS, malaria and tuberculosis.

  • Biosimilar
  • Pharmaceutical
  • United States
  • Company
  • Oncobiologics, Inc.
  • FEATURED NEWS & PRESS RELEASES

FOR SERIOUS AES THE ER/ ##PY WAS ##. ##, AND FOR SERIOUS INFECTIONS IT WAS ##. ##, WITH ## CONFIRMED CASE OF ACTIVE TUBERCULOSIS.

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Company Operations
  • Product Initiative

In ultIMMa-## one patient receiving risankizumab presented with latent tuberculosis and was treated with rifampicin.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • United States
  • Product Initiative

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Amgen Inc.

ET on Monday, May ##, 2017.

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Amgen Inc.

Kineret (anakinra) is a recombinant protein drug that blocks the biological activity of IL-##a and IL -##b by binding to interleukin-## type ## receptor (IL-R ##), expressed in a variety of tissues and organs, and thereby blocking the interleukin-## (IL-##) sign

  • Biosimilar
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Therapy
  • Pfizer Inc.

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Biosimilar
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Amgen Inc.